相关临床试验
1167
108 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
1919
Unknown
40
3.4%
已完成
720
61.7%
Enrolling By Invitation
20
1.7%
尚未招募
24
2.1%
No Longer Available
1
0.1%
终止
61
5.2%
招募中
151
12.9%
暂停
5
0.4%
Approved For Marketing
1
0.1%
撤回
80
6.9%
进行中（未招募）
64
5.5%
- USC's Viterbi School of Engineering is launching its inaugural undergraduate artificial intelligence degree, teaching students to build AI systems and apply them to fields including drug discovery, robotics, and agriculture. - UCLA is opening what officials describe as the nation's first freestanding Department of Digital Humanities, with a new bachelor's degree integrating AI and digital tools into disciplines such as sociology, archaeology, and history. - Both institutions are responding to market demand, with USC expecting roughly 50 new students annually and UCLA projecting eventual enrollment of 150 to 300 students in the major. - Educators emphasize that ethics coursework is essential, as campuses grapple with concerns about cheating and fears that heavy AI use may erode critical thinking.
- A study of more than 2.7 million patients found wait times between cancer diagnosis and first treatment have steadily grown over the last few decades. - Wait times rose from weeks to over a month across six common cancers, including breast, colon, lung, pancreatic, gastric and esophageal cancer. - Black Americans, uninsured or Medicare patients, and those treated in the West or at large academic centers were disproportionately affected by longer delays. - Every month of delayed cancer treatment can raise the risk of death by roughly 10 percent, according to prior research cited in the study.
- Researchers at the Rocky Mountain Biological Laboratory launched "OnlyMarms," a G-rated OnlyFans account, to fund their long-running yellow-bellied marmot study after federal science funding cuts threatened termination. - A marmot-themed "meme coin" named $OnlyMarms, created by outside supporters on the Solana blockchain, raised more than $88,000 in two weeks, pushing total funding past $100,000. - The combined OnlyFans and cryptocurrency funding will sustain the project for another year, though researchers acknowledge it is not an adequate substitute for standard government funding. - The 60-year study, started by Kenneth Armitage in 1962, documents climate-driven changes, including increased marmot body mass and a record die-off linked to lack of snow cover.
- Federal agencies acknowledged using keywords such as "health equity," "vaccine hesitancy," and "structural racism" to screen and terminate over 1,000 UC research grants worth nearly $2 billion. - The NIH alone suspended or cancelled more than 1,000 UC grants, including nearly 700 at UCLA, affecting vaccine research, cancer studies, and health disparities work. - Plaintiffs' lawyers argue the admissions prove First Amendment violations, unconstitutional geographic targeting, and illegal impoundment of Congressionally appropriated funds. - A court hearing on whether to skip trial and issue a final ruling restoring the grants is scheduled for October 20 before Judge Rita F. Lin.
- UCLA researchers led by Lili Yang received a $7.49 million CIRM grant to develop a universal CAR-NKT cell immunotherapy targeting multiple sclerosis. - The dual-action therapy targets CD19-expressing B cells and inflammatory myeloid cells, addressing two key drivers of MS pathology simultaneously. - Unlike patient-specific CAR-T therapies, the off-the-shelf platform uses cord blood-derived NKT cells, with estimated production costs as low as $5,000 per dose. - The team has completed a successful pre-IND meeting with the FDA and aims to achieve IND clearance with hundreds of clinical-grade doses manufactured within 2.5 years.
- The Billion Cell×Cell Project, published in Nature Biotechnology, aims to generate nearly 1 billion measurements of controlled interactions between pairs of human cells to map cellular communication systematically. - Led by Dr. Dino Di Carlo at UCLA with collaborators from USC and Caltech, the initiative will unfold in three stages: mapping gene expression changes, identifying molecular drivers, and connecting interactions to functional outcomes. - The project leverages nanovial technology—a "lab-on-a-particle" platform—enabling researchers to capture defined cell pairs and profile their interactions using widely available tools like flow cytometry and single-cell sequencing. - Insights from the cellular interaction map could inform the design of emerging therapies including CAR T cells, bispecific antibodies, engineered T cell receptors, and checkpoint inhibitors with greater precision.
- Dr. Theodore Scott Nowicki of UCLA has been awarded the $100,000 Hero Grant from MIB Agents through the OutSmarting Osteosarcoma program to develop a next-generation CAR-T cell therapy. - The novel "armed" CAR-T platform targets GD2 on osteosarcoma cells and is engineered to release TNF-alpha only in the presence of tumor cells, enhancing anti-tumor response while improving safety. - The grant will fund expanded preclinical studies comparing the TNF-alpha-armed GD2 CAR-T cells against conventional GD2 CAR-T cells in laboratory and animal models. - The research aims to address the limited effectiveness of CAR-T therapies in solid tumors by overcoming immune suppression within the tumor microenvironment.
- Amadu Tadesse, a UCLA double-major graduating this June, will spend a Fulbright year in Ethiopia establishing the country's first national pediatric cancer registry using a WHO platform. - Childhood cancer survival rates in developed nations hover around 80%, while in Ethiopia and sub-Saharan Africa they fall below 20%, driven by lack of specialists, delayed diagnoses, and absence of comprehensive data. - Tadesse has advanced a CRISPR-based gene-editing platform for cystic fibrosis and is developing CRISPR-loaded nanoparticles targeting fusion genes in alveolar rhabdomyosarcoma and mutated oncogenes in prostate cancer. - His work is shaped by dual training in biomedical science and African American Studies, focusing not only on how to cure disease but on who ultimately gains access to emerging therapies.
- UCLA researchers discovered that creatine fuels dendritic cells, the immune cells that train killer T cells to attack tumors, in addition to its previously known effects on T cells. - In mouse models of melanoma, daily creatine injections significantly slowed tumor growth and boosted both the abundance and activation of tumor-infiltrating dendritic cells. - Creatine treatment enhanced activation of human monocyte-derived dendritic cells and improved their ability to stimulate human T cells against cancer-associated targets. - The findings suggest creatine could serve as a supplement for patients receiving immunotherapy and as a manufacturing tool to improve dendritic cell-based vaccines, though human clinical trials are still needed.
- Prescriptions for ivermectin and fenbendazole among cancer patients rose 2.5-fold in early 2025 following Mel Gibson's claims on The Joe Rogan Experience, according to a JAMA Network Open study. - Researchers analyzed health records from over 68 million patients and found the steepest increases among white men and patients in the South, groups overlapping with Rogan's audience. - No human clinical trials have demonstrated that ivermectin or fenbendazole are safe or effective for treating cancer, and experts warn patients may forgo proven therapies. - The findings highlight the growing challenge of celebrity-driven health misinformation in an era where half of U.S. adults under 50 get health information from influencers.
